About enfortumab vedotin
Nectin-4-directed antibody-drug conjugate
Used for
- Treats advanced urothelial cancer, including bladder cancer, in adults.
Usual adult dose
1.25 mg/kg intravenously on days 1, 8, and 15 of each 28-day cycle; maximum 125 mg per dose.
Common side effects
- Rash and itching
- Tiredness and reduced appetite
- Numbness or tingling in hands and feet
- High blood sugar
Important warnings
- May cause severe skin reactions, including life-threatening reactions.
- Can cause high blood sugar, including diabetic ketoacidosis.
- May cause nerve damage and serious eye problems.
- Can cause lung inflammation; treatment may harm an unborn baby.
Pregnancy
May cause fetal harm. People who can become pregnant should use effective contraception during treatment and for two months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for three weeks after the last dose.
Interactions
- Strong CYP3A4 inhibitors may increase exposure to MMAE, a component of this medicine.
- Strong CYP3A4 inducers may reduce exposure to MMAE.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.